Atlas Trials

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

Clinical trial NCT06032936 · TERMINATED

Trial details

NCT number
NCT06032936
Sponsor
LianBio LLC
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
NSCLC
Start date
2023-07-27
Primary completion
2024-03-29
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.